Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION JPWA Vice President Ken Suzuki Expected to Lead JPWA After President Bessho’s Term Ends in May
March 22, 2013
-
BUSINESS Japan Pharmas Accelerating Drives to Set Up Medical Affairs Units
March 21, 2013
-
BUSINESS Alcon Japan, Kyowa Kirin Adjust Shipments of Anti-Allergy Drugs
March 19, 2013
-
ORGANIZATION Transparency Guidelines: JPMA Proposes One-Year Hold on Disclosure of Individual Payments
March 18, 2013
-
BUSINESS Eli Lilly Japan Files Tadalafil for BPH, 3rd NDA for Same API
March 15, 2013
-
REGULATORY Japan Pharmaceutical Association Vice President Hirotsugu Miura Says that 70% Rule for New Generics Will Be Debatable in Future
March 15, 2013
-
BUSINESS Sanofi Japan Aims to Enhance Leadership Status in Diabetes Sector with GLP-1, President Says
March 14, 2013
-
BUSINESS Biosimilar Makers Getting Premium-Linked Inquiries from Medical Institutions
March 13, 2013
-
BUSINESS Overseas Business Making Up for Sluggish Domestic Market; Weaker Yen Could Add Further Boost in 4th Quarter
March 13, 2013
-
BUSINESS Wholesalers’ Price Negotiations Likely to Be Carried Over to New Fiscal Year; Unsettlement Rates Could Hit Double-Digit Figures
March 12, 2013
-
BUSINESS Otsuka, Lundbeck to Expand Collaboration, Copromote Abilify in US, Europe
March 11, 2013
-
BUSINESS Sandoz Will See Accelerated Growth of Japan Operations in 2013: Global Head
March 11, 2013
-
BUSINESS Eisai to Reorganize Sales Force in Japan to Secure Aricept Market Share
March 8, 2013
-
ORGANIZATION Japan Society of Generic Medicines Calls for 80% Generic Drug Share by Volume within 5 Years
March 8, 2013
-
BUSINESS Ajinomoto to Acquire US Contract Biologic Manufacturer Althea
March 7, 2013
-
REGULATORY MHLW Approves 45 New Compounds in 2012: Mr Akagawa of PFSB
March 6, 2013
-
BUSINESS 2 SGLT-2 Inhibitors to Be Filed for Approval without Concurrent-Use Restrictions
March 5, 2013
-
BUSINESS Pfizer Positive about In-Licensing Other Firms’ Long-Listed Drugs: VP Matsumori
March 5, 2013
-
REGULATORY Lawmakers Organizing Non-Partisan Group to Break Deadlock on Establishment of 3rd-Party Drug Administration Watchdog Organization
March 5, 2013
-
BUSINESS Pfizer Japan’s Ethical Drug Sales Dip 4.2% on Lipitor Patent Expiry: FY2012 Earnings
March 4, 2013
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…